Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Lang

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Scientific Reports|November 4, 2024
A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffoldsMonja Müller, Lars Ludwig, Hanna Englert, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximabChristian A Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, et al.
Virology|September 12, 2006
Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusAmitinder Kaur, Hannah B Sanford, Deirdre Garry, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Oncoimmunology|April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesChristian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Scientific Reports|November 4, 2024
A novel stent flow chamber system demonstrates reduced thrombogenicity of bioresorbable magnesium scaffoldsMonja Müller, Lars Ludwig, Hanna Englert, et al.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximabChristian A Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, et al.
Virology|September 12, 2006
Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusAmitinder Kaur, Hannah B Sanford, Deirdre Garry, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Oncoimmunology|April 14, 2017
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokinesChristian Klein, Inja Waldhauer, Valeria G Nicolini, et al.
Mabs|May 11, 2021
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapyInja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 2